Answers are grounded in this paper and cite their sources.
Shows restoration of CD4 T cell function in a mouse model, suggesting new cancer therapies.
T cell exhaustion has been implicated in cancer and infectious diseases. In this study, we report a novel mouse model, “MolT-II”, with T cells expressing a transgenic T cell receptor (TCR) specific for a Moloney virus envelope-derived, MHC class II-presented peptide epitope. Characterization of MolT-II CD4 T cells revealed that they are dysfunctional, showing severely impaired effector functions, reduced proliferation and increased baseline expression of co-inhibitory receptors such as PD-1, LAG-3 and CTLA-4, likely due to chronic exposure to a self-antigen. We further show that epitope-specific peptide vaccination combined with immune checkpoint blockade is able to restore the function of MolT-II CD4 T cells in vivo, associated with enhanced tumor control in mice. The MolT-II mouse strain thus represents an in vivo model for reversible CD4 T cell dysfunction, allowing the study of the role of CD4 T cell regulation in cancer, mechanisms underlying CD4 T cell dysfunction and exhaustion, and novel immunomodulatory therapies aiming to rescue dysfunctional T cells. Dysfunctionality of T lymphocytes has been implicated in cancer and infection, however, the role of CD4 T cells remains understudied. The authors here generate a TCR transgenic mouse model for the study of dysfunctional CD4 T cells directed against a tumor-specific antigen, which can be reinvigorated by checkpoint blockade and vaccination.
No takes yet. Share an insight, caveat, or question.
Spitzer et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: